Pacira Pharmaceuticals Stockholders Approve Amended Incentive Plan

An announcement from Pacira Pharmaceuticals ( (PCRX) ) is now available.

On June 10, 2025, Pacira BioSciences, Inc. held its Annual Meeting of Stockholders in Parsippany, New Jersey, where stockholders approved the Amended and Restated 2011 Stock Incentive Plan, increasing the number of shares authorized for grant by 2,500,000. Additionally, the meeting included the election of directors, ratification of KPMG LLP as the accounting firm, and decisions on executive compensation, with the board opting for annual advisory votes on executive pay, reflecting a commitment to good corporate governance.

The most recent analyst rating on (PCRX) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Pacira Pharmaceuticals stock, see the PCRX Stock Forecast page.

Spark’s Take on PCRX Stock

According to Spark, TipRanks’ AI Analyst, PCRX is a Neutral.

Pacira Pharmaceuticals’ overall score is influenced by strong earnings guidance and strategic initiatives, which provide a positive outlook. However, this is tempered by weak financial performance, particularly profitability and valuation metrics, which remain significant concerns.

To see Spark’s full report on PCRX stock, click here.

More about Pacira Pharmaceuticals

Pacira BioSciences, Inc. operates in the pharmaceutical industry, focusing on providing non-opioid pain management and regenerative health solutions. The company is known for its innovative products aimed at improving patient outcomes and reducing reliance on opioids.

Average Trading Volume: 896,220

Technical Sentiment Signal: Sell

Current Market Cap: $1.13B

For a thorough assessment of PCRX stock, go to TipRanks’ Stock Analysis page.